Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (281-290 of 512) with videos related to

Pageof 52
Sort By:
Pathology, Research and Practice|November 5, 2015
Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypesVincent Thomas de Montpréville, Pauline Quilhot, Lara Chalabreysse, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancerByoung Chul Cho, Grace K Dy, Ramaswamy Govindan, et al.
Virchows Archiv : an International Journal of Pathology|April 15, 2021
Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)Francesca Fenizia, Nicola Wolstenholme, Jennifer A Fairley, et al.
Journal for Immunotherapy of Cancer|May 26, 2022
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodiesMathieu Larroquette, Jean-Philippe Guegan, Benjamin Besse, et al.
Cell Cycle (Georgetown, Tex.)|January 25, 2013
Prognostic value of LIPC in non-small cell lung carcinomaLorenzo Galluzzi, Aicha Goubar, Ken André Olaussen, et al.
Lung Cancer (Amsterdam, Netherlands)|January 10, 2024
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastasesSolange Peters, José Trigo, Benjamin Besse, et al.
JAMA Oncology|April 9, 2026
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received PembrolizumabAdrien Rousseau, Stéphanie Foulon, David Planchard, et al.
NPJ Precision Oncology|May 13, 2026
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinibMai Nagasaka, Francesco Facchinetti, Ludovic Bigot, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2017
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancerJean-Charles Soria, Alex A Adjei, Rastilav Bahleda, et al.
Clinical Lung Cancer|May 12, 2026
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLCMarina Chiara Garassino, Sophie Cousin, Benjamin Besse, et al.
Pageof 52

Showing results (281-290 of 512) with videos related to

Sort By:
Pageof 52
Pathology, Research and Practice|November 5, 2015
Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypesVincent Thomas de Montpréville, Pauline Quilhot, Lara Chalabreysse, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancerByoung Chul Cho, Grace K Dy, Ramaswamy Govindan, et al.
Virchows Archiv : an International Journal of Pathology|April 15, 2021
Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)Francesca Fenizia, Nicola Wolstenholme, Jennifer A Fairley, et al.
Journal for Immunotherapy of Cancer|May 26, 2022
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodiesMathieu Larroquette, Jean-Philippe Guegan, Benjamin Besse, et al.
Cell Cycle (Georgetown, Tex.)|January 25, 2013
Prognostic value of LIPC in non-small cell lung carcinomaLorenzo Galluzzi, Aicha Goubar, Ken André Olaussen, et al.
Lung Cancer (Amsterdam, Netherlands)|January 10, 2024
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastasesSolange Peters, José Trigo, Benjamin Besse, et al.
JAMA Oncology|April 9, 2026
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received PembrolizumabAdrien Rousseau, Stéphanie Foulon, David Planchard, et al.
NPJ Precision Oncology|May 13, 2026
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinibMai Nagasaka, Francesco Facchinetti, Ludovic Bigot, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2017
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancerJean-Charles Soria, Alex A Adjei, Rastilav Bahleda, et al.
Clinical Lung Cancer|May 12, 2026
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLCMarina Chiara Garassino, Sophie Cousin, Benjamin Besse, et al.
Pageof 52